Richard Newcomb Stillwell Buys 5,000 Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Director Richard Newcomb Stillwell acquired 5,000 shares of the stock in a transaction on Monday, June 8th. The shares were acquired at an average price of $11.65 per share, for a total transaction of $58,250.00. Following the acquisition, the director owned 5,000 shares of the company’s stock, valued at approximately $58,250. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Tonix Pharmaceuticals Trading Down 4.4%

TNXP opened at $10.96 on Thursday. The company’s fifty day moving average price is $13.15 and its two-hundred day moving average price is $14.99. Tonix Pharmaceuticals Holding Corp. has a 1-year low of $10.87 and a 1-year high of $69.97. The company has a market cap of $174.70 million, a price-to-earnings ratio of -0.76 and a beta of 1.67.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Monday, May 11th. The company reported ($2.93) earnings per share for the quarter, missing the consensus estimate of ($2.54) by ($0.39). Tonix Pharmaceuticals had a negative return on equity of 67.65% and a negative net margin of 839.52%.The business had revenue of $6.88 million for the quarter, compared to analyst estimates of $6.13 million. As a group, equities analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -9.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc bought a new position in Tonix Pharmaceuticals during the second quarter valued at about $25,000. State of Wyoming bought a new position in Tonix Pharmaceuticals during the fourth quarter valued at about $27,000. Russell Investments Group Ltd. bought a new stake in shares of Tonix Pharmaceuticals in the 3rd quarter worth approximately $29,000. BNP Paribas Financial Markets bought a new stake in shares of Tonix Pharmaceuticals in the 2nd quarter worth approximately $65,000. Finally, Leonteq Securities AG purchased a new position in Tonix Pharmaceuticals in the fourth quarter valued at approximately $89,000. Institutional investors own 82.26% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on TNXP shares. Weiss Ratings restated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a report on Monday, April 20th. TD Cowen upgraded shares of Tonix Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, May 5th. Finally, Wall Street Zen downgraded shares of Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, April 26th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $22.00.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.